Evidence-based guideline update: Plasmapheresis in neurologic disorders [RETIRED]: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
To reassess the role of plasmapheresis in the treatment of neurologic disorders.



We evaluated the available evidence based on a structured literature review for relevant articles from 1995 through September 2009. In addition, due to revision of the definitions of classification of evidence since the publication of the previous American Academy of Neurology assessment in 1996, the evidence cited in that manuscript was reviewed and reclassified.



Plasmapheresis is established as effective and should be offered in severe acute inflammatory demyelinating polyneuropathy (AIDP)/Guillain-Barré syndrome (GBS) and in the short-term management of chronic inflammatory demyelinating polyneuropathy (Class I studies, Level A). Plasmapheresis is established as ineffective and should not be offered for chronic or secondary progressive multiple sclerosis (MS) (Class I studies, Level A). Plasmapheresis is probably effective and should be considered for mild AIDP/GBS, as second-line treatment of steroid-resistant exacerbations in relapsing forms of MS, and for neuropathy associated with immunoglobulin A or immunoglobulin G gammopathy, based on at least one Class I or 2 Class II studies (Level B). Plasmapheresis is probably not effective and should not be considered for neuropathy associated with immunoglobulin M gammopathy, based on one Class I study (Level B). Plasmapheresis is possibly effective and may be considered for acute fulminant demyelinating CNS disease (Level C). There is insufficient evidence to support or refute the use of plasmapheresis for myasthenia gravis, pediatric autoimmune neuropsychiatric disorders associated with streptococcus infection, and Sydenham chorea (Class III evidence, Level U).
National Institutes of Health, Bethesda, USA.
I
I
Cortese
V
V
Chaudhry
Y T
YT
So
F
F
Cantor
D R
DR
Cornblath
A
A
Rae-Grant
D002493:Central Nervous System Diseases / Q000628:therapy*; D003711:Demyelinating Diseases / Q000628:therapy; D019317:Evidence-Based Medicine; D020275:Guillain-Barre Syndrome / Q000628:therapy; D006801:Humans; D007070:Immunoglobulin A / Q000097:blood; D007074:Immunoglobulin G / Q000097:blood; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000628:therapy; D009157:Myasthenia Gravis / Q000628:therapy; D010265:Paraproteinemias / Q000628:therapy; D010523:Peripheral Nervous System Diseases / Q000628:therapy*; D010956:Plasmapheresis; D011115:Polyneuropathies / Q000628:therapy; D017410:Practice Guidelines as Topic / Q000592:standards*
D007070:Immunoglobulin A; D007074:Immunoglobulin G
Jpn J Thorac Cardiovasc Surg. 2005 Jan;53(1):2-7
15724495
Neurology. 1996 Sep;47(3):840-3
8797493
Brain. 1996 Aug;119 ( Pt 4):1055-66
8813270
Lancet. 1991 Feb 23;337(8739):441-6
1671468
J Neurol Neurosurg Psychiatry. 1995 Sep;59(3):243-7
7673949
Neurology. 1989 Sep;39(9):1143-9
2549450
Ann Neurol. 1997 Mar;41(3):298-306
9066350
Neurology. 1985 Aug;35(8):1096-104
4022342
Ann Neurol. 2001 Aug;50(2):195-201
11506402
Lancet. 1999 Oct 2;354(9185):1153-8
10513708
N Engl J Med. 1991 Nov 21;325(21):1482-6
1658648
Neurology. 1996 Jun;46(6):1620-5
8649560
Ann Neurol. 1994 Dec;36(6):838-45
7998769
Ann Neurol. 1999 Dec;46(6):878-86
10589540
Lancet. 1997 Jan 25;349(9047):225-30
9014908
Can J Neurol Sci. 1985 Feb;12(1):39-44
3884114
N Engl J Med. 1992 Apr 23;326(17):1123-9
1552913
Neurology. 2009 Feb 3;72(5):402-9
19188571
N Engl J Med. 1986 Feb 20;314(8):461-5
3511382
Pediatrics. 2004 Apr;113(4):883-6
15060240
Neurology. 1985 Mar;35(3):312-9
3974889
Ann Neurol. 1987 Dec;22(6):753-61
2893583
Neurology. 1996 Jan;46(1):100-3
8559353
Neurology. 1987 May;37(5):837-40
3553986
J Child Neurol. 2005 May;20(5):424-9
15968928
Thorax. 1995 Oct;50(10):1080-6
7491557
Pediatrics. 2004 Apr;113(4):907-11
15060242